Within the protein sequencing market, Protein Sequencing Products held the strongest position in 2025 with a 76.86% share. This leadership is maintained through the routine and recurring need for instruments, reagents, consumables, and related workflow components across laboratories performing in-house sequencing work. Demand remains concentrated in products because research and testing facilities often require direct control over sample preparation, sequencing workflows, and result validation, making product ownership central to daily operations in the protein sequencing market.

Protein Sequencing Services are emerging as the fastest-growing part of the protein sequencing market as more end users seek access to specialized sequencing capabilities without committing to full internal infrastructure. Growth is being reinforced through the practical need for outsourced expertise, especially where workflows are technically demanding, sample volumes fluctuate, or organizations want faster access to advanced analysis capacity than building it internally. Relative to products, services gain momentum when flexibility, turnaround efficiency, and access to specialized know-how become more important than capital investment.

End Use Segment Analysis: Academic Institutes & Research Centers (Largest Segment) vs Pharmaceutical & Biotechnology Companies (Fastest-Growing Segment)

Academic Institutes & Research Centers accounted for the largest position in the protein sequencing market in 2025, holding a 51.94% share. Their leadership reflects the strong concentration of protein analysis activity in basic research, translational studies, and university-led life sciences programs where sequencing is used extensively to investigate protein structure, function, and biological pathways. The segment’s share remains high because academic and research environments generate a steady flow of discovery-oriented projects that depend on protein sequencing tools and workflows as a core part of laboratory research.

Pharmaceutical & Biotechnology Companies represent the fastest-growing end-use segment in the protein sequencing market, encouraged by the increasing need to characterize complex biologics and support development workflows with high-confidence protein analysis. Growth is stronger in this segment because sequencing is becoming more closely tied to applied commercial requirements, including drug discovery, therapeutic validation, and product development processes where analytical precision has direct operational value. Compared with academic users, these companies are expanding usage in response to development timelines and product-focused research demands that require deeper and more frequent protein characterization.